

1.	<p>Treatment & Condition</p> <p>Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure</p>
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology Appraisal guidance TA626 (July 2020)</p> <p>Avatrombopag (Doptelet) is recommended, within its marketing authorisation, as an option for treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.</p>
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>It is estimated that there will be 8 patients in year 1 eligible for treatment in line with this guidance. This is estimated to increase to 33 patients per annum in Northern Ireland by year 5.</p>
4.	<p>Patient Access Scheme Availability</p> <p>(Yes/<u>No</u>)</p>
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated will be dealt with as part of the routine commissioning process.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis. Thereafter, numbers of patients who received or are receiving treatment will be reviewed and consideration will be given to moving to recurrent funding to support this regimen</p>
8.	<p>Monitoring arrangements</p> <p>The use of this drug will be monitored through the cost per case process.</p>
9.	<p>DoH (NI) Legislative/Policy Caveats</p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for</p>

	<p>example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>
--	---